Proceedings of the 2nd Global Health and Innovation in conjunction with 6th ORL Head and Neck Oncology Conference (ORLHN 2021)

<Previous Article In Volume
Next Article In Volume>

Polypharmacy as a Risk Factor for Exanthematous Drug Eruption

Authors
Lalu Shalya Kusuma Putra1, *, Lisa Alverina2, Dedianto Hidajat3, 4
1Medical Profession Study Program, Faculty of Medicine, University of Mataram, Indonesia
2Dermatology and Venereology Department, West Nusa Tenggara General Hospital, Indonesia
3Dermatology and Venereology Department, Faculty of Medicine, University of Mataram, Indonesia
4West Nusa Tenggara General Hospital, Indonesia
*Corresponding author. Email: shalya0101@gmail.com
Corresponding Author
Lalu Shalya Kusuma Putra
Available Online 21 February 2022.
DOI
10.2991/ahsr.k.220206.008How to use a DOI?
Keywords
Exanthemata’s drug eruption; Polypharmacy; Ceftriaxone; Paracetamol; Phenytoin
Abstract

Cutaneous adverse drug reactions (CADR) are an unfavorable condition caused by drugs manifesting on the skin. Exanthemata’s drug eruption is the most common manifestation. The symptoms are itchy rash and burning sensation at the lesion and can occur along with fever and pain. The most common types of drugs inducing CADR are antibiotics, non-steroidal, anti-inflammatory drugs (NSAID), and anticonvulsants. A 48-year-old woman with complaints of itching on the chest followed by both arms and legs. Complaints arose 8 days after surgical excision of the craniometrical tumors when the patient was treated with polypharmacy medications. The description of the lesions is regional, multiple, well-defined maculopapular lesions with erythema, crusts, and excoriation. The working diagnosis is exanthemata’s drug eruption with ceftriaxone, paracetamol, and phenytoin as the suspected causative drugs. No history of drug allergy was known before. Polypharmacy can cause difficulty in making clinical decisions for discontinuing the suspected drugs and cause patient’s comorbidity left untreated. Therefore, it is important to identify the type of drugs and drug interaction causing cutaneous adverse drug reactions and minimize the use of polypharmacy therapy if possible.

Copyright
© 2022 The Authors. Published by Atlantis Press International B.V.
Open Access
This is an open access article under the CC BY-NC license.

Download article (PDF)

<Previous Article In Volume
Next Article In Volume>
Volume Title
Proceedings of the 2nd Global Health and Innovation in conjunction with 6th ORL Head and Neck Oncology Conference (ORLHN 2021)
Series
Advances in Health Sciences Research
Publication Date
21 February 2022
ISBN
978-94-6239-540-4
ISSN
2468-5739
DOI
10.2991/ahsr.k.220206.008How to use a DOI?
Copyright
© 2022 The Authors. Published by Atlantis Press International B.V.
Open Access
This is an open access article under the CC BY-NC license.

Cite this article

risenwbib
TY  - CONF
AU  - Lalu Shalya Kusuma Putra
AU  - Lisa Alverina
AU  - Dedianto Hidajat
PY  - 2022
DA  - 2022/02/21
TI  - Polypharmacy as a Risk Factor for Exanthematous Drug Eruption
BT  - Proceedings of the 2nd Global Health and Innovation in conjunction with 6th ORL Head and Neck Oncology Conference (ORLHN 2021)
PB  - Atlantis Press
SP  - 35
EP  - 38
SN  - 2468-5739
UR  - https://doi.org/10.2991/ahsr.k.220206.008
DO  - 10.2991/ahsr.k.220206.008
ID  - Putra2022
ER  -